A. van Wijk

Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the Lung

G. Peters, P. Postmus, R. Perez-soler, 2007, Clinical Cancer Research.

Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.

E. Smit, P. Postmus, E. Thunnissen, 2014, Lung cancer.

Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.

E. Smit, P. Postmus, F. Thunnissen, 2011, European journal of cancer.

High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib.

E. Smit, P. Postmus, E. Thunnissen, 2014, European journal of cancer.

A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non–Small Cell Lung Cancer with a KRAS Mutation

H. Groen, E. Smit, E. Thunnissen, 2012, Clinical Cancer Research.

Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: results from 2 phase I studies.

R. Vernhout, K. Nackaerts, R. V. van Klaveren, 2010, Lung cancer.

Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer

E. Smit, P. Postmus, A. Becker, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.